FMED Performance — Fidelity Disruptive Medicine ETF
Data updated: 2026-09-24
FMED returned −6.86% year to date and +8.04% over one year to May 2026. Over one year the fund trailed its Thematic Equity category average: $100 grew to $108, against $125 for the category. Volatility over the past 12 months was 14.97% a year. In the 12 months to May 2026 the fund lost a net $12.2M, and assets reached $40.98M.
FMED Growth of $100
What $100 invested in Fidelity Disruptive Medicine ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Thematic Equity category average over the same months.
| Period | FMED | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $108 | $125 |
| Since data start (Jul 2023 – May 2026) | $101 | $165 |
FMED Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −6.86% |
| 1 year | +8.04% |
| 3 years (annualised) | +0.28% |
FMED Annual Returns
Calendar-year total returns of Fidelity Disruptive Medicine ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | −6.86% |
| 2025 | +9.70% |
| 2024 | +2.45% |
| 2023 (Jul–Dec) | −3.68% |
FMED Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.3% | −2.0% | −6.3% | +1.0% | +1.6% | — | — | — | — | — | — | — |
| 2025 | +6.5% | −4.2% | −6.1% | +1.3% | −2.5% | +2.8% | −1.3% | +3.6% | +2.0% | +5.0% | +9.0% | −5.5% |
| 2024 | −0.4% | +4.2% | +1.3% | −6.1% | −1.6% | +2.3% | +2.8% | +5.3% | +1.3% | −3.2% | +2.7% | −5.4% |
| 2023 | — | — | — | — | — | — | +1.0% | −6.0% | −7.3% | −8.4% | +6.4% | +12.4% |
FMED Risk
Risk measures from monthly returns over Jun 2025 – May 2026.
- 1-year volatility (annualised): 14.97%
- Best month: +9.05% (Nov 2025)
- Worst month: −6.29% (Mar 2026)
FMED Fund Flows
Monthly money in and out of Fidelity Disruptive Medicine ETF, from SEC Form N-PORT.
- 12-month net flow: −$12.2M
- 12-month gross sales (incl. reinvestments): $5.1M
- Sales ÷ redemptions: 0.29×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $17.4M | −$17.4M |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $0 | $0 | $0 |
| Feb 2026 | $0 | $0 | $0 |
| Jan 2026 | $0 | $0 | $0 |
| Dec 2025 | $2.8M | $0 | $2.8M |
| Nov 2025 | $0 | $0 | $0 |
| Oct 2025 | $0 | $0 | $0 |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $0 | $0 |
| Jul 2025 | $0 | $0 | $0 |
| Jun 2025 | $2.4M | $0 | $2.4M |
FMED Assets Under Management
Net assets of Fidelity Disruptive Medicine ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $40.98M |
| 2026-02-28 | $60.94M |
| 2025-11-30 | $63.74M |
| 2025-08-31 | $54.58M |
| 2025-05-31 | $49.61M |
| 2025-02-28 | $53.55M |
| 2024-11-30 | $55.70M |
| 2024-08-31 | $55.31M |
| 2024-05-31 | $49.93M |
| 2024-02-29 | $53.37M |
| 2023-11-30 | $45.77M |
| 2023-08-31 | $41.14M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.